دورية أكاديمية
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products
| العنوان: | ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products |
|---|---|
| المؤلفون: | Talarico, R., Ramirez, G. A., Barreira, S. C., Cardamone, C., Triggianese, P., Aguilera, S., Andersen, J., Avcin, T., Benistan, K., Bertsias, G., Bortoluzzi, A., Bouillot, C., Bulina, I., Burmester, G. R., Callens, S., Carreira, P. E., Cervera, R., Cutolo, M., Damian, L., Della Torre, E., Faria, R., Fonseca, J. E., Galetti, I., Hachulla, Eric, Iaccarino, L., Jacobsen, S., Khmelinskii, N., Limper, M., Marinello, D., Meyer, A., Moroncini, G., Nagy, G., Olesinska, M., Pamfil, C., Pileckyte, M., Pistello, M., Rednic, S., Richez, C., Romao, V. C., Schneider, M., Sciascia, S., Scira, C. A., Simonini, G., Smith, V., Sulli, A., Tani, C., Tas, S. W., Tincani, A., Vonk, M. C., Tektonidou, M., Mosca, M. |
| المساهمون: | Université de Lille, Inserm, CHU Lille, Azienda Ospedaliero-Universitaria Pisana = Cisanello University Hospital Pisa, IRCCS Ospedale San Raffaele Milan, Italy, Universidade de Lisboa, Università degli Studi di Salerno = University of Salerno UNISA, University of Rome Tor Vergata, University Medical Centre Ljubljana Ljubljana, Slovenia UMCL, Hôpital Raymond Poincaré (Garches) GHU AP-HP Université Paris-Saclay, University of Crete Heraklion UOC, Università degli Studi di Ferrara = University of Ferrara UniFE, Riga Stradins University RSU, Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin HU Berlin, Ghent University Hospital, Hospital Universitario 12 de Octubre Madrid, Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Istituto di ricovero e cura a carattere scientifico Azienda Ospedaliera Universitaria "San Martino" IRCCS AOU San Martino, Technical University of Cluj-Napoca, Ospedale San Raffaele, Universidade do Porto = University of Porto, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Azienda Ospedale Università di Padova = Hospital-University of Padua AOUP, Rigshospitalet Copenhagen, Universiteit Utrecht / Utrecht University Utrecht, Centre Hospitalier Universitaire Strasbourg CHU Strasbourg, Polytechnic University of Marche Ancona, Italy / Università Politecnica delle Marche Ancona, Italia UNIVPM, Semmelweis University of Medicine Budapest, Warsaw University of Technology Warsaw, Kaunas University of Technology KTU, University of Pisa - Università di Pisa, Babes-Bolyai University Cluj-Napoca UBB, CHU de Bordeaux Pellegrin Bordeaux, University Hospital Düsseldorf, 60273|||Università degli Studi di Milano-Bicocca = University of Milano-Bicocca UNIMIB (VALID), Università degli Studi di Firenze = University of Florence = Université de Florence UniFI, University of Amsterdam Amsterdam = Universiteit van Amsterdam UvA, Università degli Studi di Brescia = University of Brescia UniBs, Radboud University Medical Center Nijmegen, National and Kapodistrian University of Athens NKUA |
| سنة النشر: | 2024 |
| المجموعة: | LillOA (Lille Open Archive - Université de Lille) |
| مصطلحات موضوعية: | European Reference Networks, COVID-19, antiviral drugs, monoclonal antibodies, rare and complex diseases, rheumatic and musculoskeletal diseases, connective tissue diseases, patient care, European Commission |
| الوصف: | Recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So far, some autoimmune rheumatic disease (ARD) patients with COVID-19 have been treated with antiviral therapies or anti-SARS-CoV-2 antibody products. However, there is no homogeneous approach to these treatment strategies. This issue was addressed within the European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) in a discussion among experts and patient’s representatives in the context of the rare and complex connective tissue diseases (rCTDs) covered by the Network. ERN ReCONNET is one of the 24 ERNs launched by the European Commission in 2017 with the aim of tackling low prevalence and rare diseases that require highly specialised treatment and promoting concentration of knowledge and resources through virtual networks involving healthcare providers (HCPs) across the European Union (EU). Considering the urgent need to provide guidance not only to the rCTDs community, but also to the whole ARDs community, a multidisciplinary Task Force, including expert clinicians and European Patient Advocacy Group (ePAG) Advocates, was created in the framework of ERN ReCONNET with the aim of developing overarching principles (OP) and points-to-consider (PtC) on a homogenous approach to treat immunocompromised patients with ARDs (with a particular focus on CTDs) affected by COVID-19 using antiviral therapies and anti-SARS-CoV-2 antibody products. The present work reports the final OP and PtC agreed by the Task Force. ; 41 |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/octet-stream |
| اللغة: | English |
| العلاقة: | Clinical and experimental rheumatology; Clin. Exp. Rheumatol.; http://hdl.handle.net/20.500.12210/106455Test |
| الإتاحة: | https://doi.org/20.500.12210/106455Test https://hdl.handle.net/20.500.12210/106455Test |
| رقم الانضمام: | edsbas.8B2BDDAD |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |